Q-omics provides the consensus-scored NT5E profile across patient tissues and cancer cell-line models. NT5E expression is associated with patient survival in 24 of 34 cancer types, with the highest sampling consensus in STAD. Among the 18 cancer types available for tumor–normal comparison, NT5E is differentially expressed in 15, with the highest sampling consensus in HNSC. Additionally, NT5E protein abundance shows 23,231 significant protein co-abundance associations, with the highest sampling consensus in UCEC. Together, these results highlight STAD, HNSC, and UCEC as cancer lineages where NT5E shows reproducible signals across survival, tumor–normal expression, and patient cross-omics analyses.
Every result is evaluated using two consensus scores. Sampling consensus measures how consistently a finding is reproduced within a cancer lineage across different conditions. Lineage consensus measures how broadly the result is shared across cancer types, distinguishing pan-cancer signals from lineage-specific patterns.
Premium analyses for NT5E — synthetic lethality, tumor antigen, and pembrolizumab response.
This table summarizes NT5E survival associations across molecular data types. NT5E RNA expression shows survival associations in the most cancer types (24), followed by mutation status (6) and mass-spec protein abundance (7). The rightmost column indicates the cancer type with the highest sampling consensus for each molecular layer.
This table ranks reproducible NT5E RNA expression–survival associations across cancer types. High NT5E expression shows unfavorable associations in STAD, UVM, HNSC, MESO, LUSC and PAAD. The STAD Kaplan–Meier curve shows clear separation, with the high-expression group declining faster, consistent with the unfavorable association (log-rank p < 0.001). Together, the overview and detailed table identify STAD as the clearest survival context for NT5E RNA expression.
This table summarizes NT5E tumor–normal expression differences by data type. RNA shows broader differences across cancer types, with a lineage consensus of 15, while mass-spec protein shows differences in 7. The strongest signals are observed in HNSC for RNA and COAD for protein.
This table ranks reproducible tumor–normal expression differences for NT5E. A negative fold-change indicates higher expression in normal tissue than in tumor tissue. NT5E shows lower tumor expression in UCEC and BLCA and higher tumor expression in HNSC, LUAD, KIRC and THCA. The HNSC box plot shows higher NT5E RNA expression in tumor versus normal tissue (log2 FC = +3.440, t-test p < 0.001).
This table shows molecular features associated with NT5E in patient tissues and cancer cell lines. In patient samples, NT5E shows the broadest associations at the RNA and protein expression levels, with UCEC recurring as the lineage with the largest associated feature set. In cancer cell lines, NT5E RNA and mutation anchors are most strongly linked to RNA-expression features, especially in OVARY, while CRISPR and shRNA rows add functional-dependency signals in BONE and UPPER_AERODIGESTIVE_TRACT.
